Actualités et vidéos - PIXIUM VISION - Anglais

Pixium Vision announces the opening of safeguard proceedings Paris, France, October 9, 202 3 – 19:00 (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX) (the “ Company ”), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces the opening today of safeguard proceedings by the Commercial Court of Paris. Indeed, despite all the efforts made in the research of financing...

Pixium Vision announces the implementation of a bridge financing with Bpifrance and Sofinnova and a reverse stock split on the basis of 1 new share for 50 existing shares Bridge financing: 3 million Euro convertible shareholders’ loan from Bpifrance and Sofinnova to extend c ash runway to the end of November 2023 Publication of half-year financial statements postponed to September 2023 Reverse stock split: implementation of a reverse stock split process - allocation of 1 new ordinary share...

Pixium Vision announces the agreement to extend the maturity date of the outstanding notes associated with the terminated ESGO financing facility Paris, France, Ju ly 11 , 202 3 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that it successfully negotiated an extension of the maturity date,...

Annual Meeting of Shareholders June 1 3 , 202 3 Availability of preparatory documents Paris, France , May 2 4 , 202 3 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that its Annual Meeting of the Company will be held on June 13, 2023, at 2.00 pm CET at the headquarter of Pixium Vision, 74 rue du...

Pixium Vision announces its consolidated financial statements for the financial year 202 2 and the consolidated cash balance for March 31 , 2023 Paris, April 21 , 202 3 – 7.00 a.m. CET - Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces that the consolidated financial statements for the year 2022 were approved by Pixium Vision’s...

Communication following the announcemen t of FDA Breakthrough Device Designation for the Prima System in Dry AMD Conversion of 160 ORNAN2022 by ESGO with intention to pursue controlled trading of shares Cost reduction measures implemented potentially extending the cash runway beyond the end of Q2 2023 Continuation of the fundraising process Breakthrough Device Designation status to streamline FDA regulatory review process Paris, April 3 , 202 3 – 7:00 CET – Pixium Vision SA (Euronext Growth...

Second convening of the Extraordinary Shareholder Meeting on March 8, 2023 Paris, France, February 16 , 2023 – 6.00 pm CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that its extraordinary shareholder meeting, convened a second call to vote on the same agenda as the extraordinary shareholder meeting of...

Pixium Vision welcomes j udgment by Paris Commercial Court against Second Sight Medical Products Court finds Second Sight Medical Products breached 2021 contractual obligations to Pixium Vision Court orders Second Sight Medical Products to pay Pixium Vision an additional €1.58 million in costs and damages Paris, France, December 2 8 , 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision...

Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024 38 patients have been implanted with Prima System in pivotal trial Data will also play an important supporting role in US regulatory submission Paris, France, December 15 , 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops...

Pixium Vision announces its cash position at 3 0 September 202 2 and provides an update on its activities Paris, 2 1 October 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today a cash position of €8.5 million at 30 September 2022 and reports on its key developments. Statement of cash flows...

Pixium Vision announces participation in investor conferences and events in October 2022 Paris, France, October 4 , 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following investor events in October 2022: Biotech Agora , October 12, Paris...

Pixium Vision announces participation in upcoming investor conferences in September 2022 Paris, France, September 6 , 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following investor conferences during September 2022: H . C . Wainwright 24...

Pixium Vision announces participation in upcoming scientific conferences in September 2022 Paris, France, August 29 , 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following scientific conferences during September 2022: 22 nd E URETINA...

Pixium Vision to attend H.C. Wainwright 2 nd Annual Ophthalmology Virtual Conference on August 17, 2022 Paris, France , August 11 , 202 2 – 19:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend virtually the H.C. Wainwright 2 nd...

Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera PRIMAvera clinical site opens at the Rotterdam Eye Hospital in the Netherlands Follows successful implantations at clinical sites in France, Germany and the UK New clinical sites to open in Spain and Italy PRIMAvera read-out expected around the end of 2023 Paris, France, Ju ly 26 , 202 2 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641;...

Pixium Vision announces its financial results for H1 2022 and provides a b usiness update Cash position at 30 June 2022: €7,2 million PRIMAvera European pivotal study ongoing and on track to report data around end 2023 Post period event: Implementation of a convertible note financing agreement with a maximum nominal amount of €30 million with ESGO, potentially extending cash runway until the middle of 2024, assuming all tranches are drawn 1 Drawdown of the first tranche with a nominal value...

Pixium Vision announces the availability of its audited financial statements for the financial year 2021 Paris, 29 April 202 2 – 7.00 p.m. CET - Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces that its audited financial statements for the year 2021 have been made available on the company’s website. The 2021 financial statements...

R esults of Combined General Meeting held on April 19, 2022 Annual General Meeting of Shareholders to be held on June 22, 2022 Paris, France , April 28 , 202 2 – 07:00 CET – The Combined Shareholders Meeting of Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, was held in Paris on on April 19, 2022 and adopted all the...

Pixium Vision announces its cash position at 31 March 202 2 and provides an update on its activities and financial outlook until the end of 202 2 Paris, France , April 19 , 202 2 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces a cash position of €10.4 million at 31 March 2022 and reports on its key developments. In...

Combined General Meeting of April 19, 2022: Availability of preparatory documents Paris, France , April 4, 202 2 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that the prior notice of the Combined General Meeting containing the agenda, the draft resolutions presented by the Board of Directors for agreement...